Maravai LifeSciences (MRVI) Projected to Release Earnings on Wednesday

Maravai LifeSciences (NASDAQ:MRVI) is expected to be announcing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Maravai LifeSciences to post earnings of ($0.0563) per share and revenue of $43.56 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 5:00 PM ET.

Maravai LifeSciences (NASDAQ:MRVI) last posted its earnings results on Thursday, August 6th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.02. The firm had revenue of $51.44 million during the quarter, compared to the consensus estimate of $48.67 million. On average, analysts expect Maravai LifeSciences to post ($0.18) EPS for the current fiscal year and ($0.13) EPS for the next fiscal year.

Maravai LifeSciences Stock Performance

NASDAQ MRVI traded up $0.07 on Wednesday, reaching $8.34. 317,302 shares of the stock traded hands, compared to its average volume of 2,473,369. The firm’s fifty day simple moving average is $7.43 and its 200 day simple moving average is $5.17. Maravai LifeSciences has a 12 month low of $2.55 and a 12 month high of $9.42.

Analysts Set New Price Targets

Several research firms have weighed in on MRVI. UBS Group raised their target price on Maravai LifeSciences from $2.50 to $8.00 and gave the company a “neutral” rating in a report on Wednesday, September 9th. TD Cowen assumed coverage on Maravai LifeSciences in a research note on Monday, October 5th. They set a “buy” rating and a $9.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maravai LifeSciences in a research note on Wednesday, August 26th. Wall Street Zen lowered shares of Maravai LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, August 29th. Finally, Wells Fargo & Company boosted their price target on Maravai LifeSciences from $5.50 to $6.50 and gave the company an “overweight” rating in a research note on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Maravai LifeSciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.38.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc is a life sciences company that provides products and services used in the development, manufacture and quality testing of biopharmaceuticals, vaccines and diagnostic products. The company serves pharmaceutical, biotechnology, academic and other research organizations involved in nucleic acid and biologics development.

Through its TriLink BioTechnologies business, Maravai supplies specialized nucleic acid products and services, including modified nucleotides, messenger RNA-related materials, enzymes and other components used in research and biomanufacturing.